Comparative clinical outcomes and single-cell profiling of CD19 CAR-T versus blinatumomab for relapsed/refractory B-ALL
Journal for ImmunoTherapy of Cancer · 2026-09 · 14 (9) · e015196
DOI: 10.1136/jitc-2026-015196 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 28.09.2026. Verfasst von Kexin Wang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Antigens, CD19, Immunotherapy, Adoptive, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
BACKGROUND: CD19-targeting chimeric antigen receptor T-cells (CAR-T) and blinatumomab represent two leading immunotherapies for relapsed/refractory B cell acute lymphoblastic leukemia (r/r B-ALL). Despite sharing the same target, their differential clinical efficacy and underlying mechanisms remain unclear. METHODS: This retrospective study enrolled 106 r/r B-ALL patients (61 CD19 CAR-T vs 45 blinatumomab) between February 2020 and August 2023. The complete response (CR) rate, long-term survival, and therapeutic toxicities were compared between the two cohorts. Additionally, we conducted scRNA-seq on nine samples of patient-derived CAR-T/ blinatumomab-elicited T cells after infusion and performed a head-to-head comparison in vitro. RESULTS: Overall, the CR or CR with incomplete count recovery (CR/CRi) rate by day 28 after infusion was 96.6% (56/58) in the CAR-T cohort and 77.8% (35/45) in the blinatumomab cohort (p=0.008). With a median follow-up of 10 months (IQR 5.0-19.4), overall survival (OS) and leukemia-free survival (LFS) were comparable. In patients with higher tumor burden (minimal residual disease >20%), CAR-T was associated with a longer LFS (HR 0.453, 95% CI 0.226 to 0.908, p=0.026) compared with blinatumomab. In patients with relapsed disease, CAR-T showed prolonged LFS (HR 0.415, 95% CI 0.221 to 0.778, p=0.006) and a trend toward improved OS (p=0.088). All toxicities were reversible, and any adverse events (AEs) were similar (98.4% vs 88.9%), but severe AEs (grade ≥3) were higher with CAR-T, especially cytokine release syndrome (42.6% vs 13.3%, p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
- Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
- Wenzhou Medical University, Wenzhou, Zhejiang, China.
- Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China huanghe@zju.edu.cn 1313016@zju.edu.cn dongrui-wang@zju.edu.cn weiguoqing2018@zju.edu.c…
- Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wang, K., Yu, L., Liang, X., Song, F., Jiang, S., Han, S., Zhang, M., Liu, K., Wen, R., Jin, L., Xiong, Y., Qiu, Y., Xu, H., Wei, G., Wang, D., Hu, Y., & Huang, H. (2026). Comparative clinical outcomes and single-cell profiling of CD19 CAR-T versus blinatumomab for relapsed/refractory B-ALL. Journal for ImmunoTherapy of Cancer, 14(9), e015196. https://doi.org/10.1136/jitc-2026-015196
Vancouver
Wang K, Yu L, Liang X, Song F, Jiang S, Han S, et al. Comparative clinical outcomes and single-cell profiling of CD19 CAR-T versus blinatumomab for relapsed/refractory B-ALL. Journal for ImmunoTherapy of Cancer. 2026;14(9):e015196. doi:10.1136/jitc-2026-015196
BibTeX
@article{Wang2026,
author = {Wang, Kexin and Yu, Leijin and Liang, Xinghua and Song, Fengmei and Jiang, Songfu and Han, Shi and Zhang, Mingming and Liu, Kai and Wen, Rui and Jin, Lele and Xiong, Yao and Qiu, Yunfei and Xu, Huijun and Wei, Guoqing and Wang, Dongrui and Hu, Yongxian and Huang, He},
title = {Comparative clinical outcomes and single-cell profiling of CD19 CAR-T versus blinatumomab for relapsed/refractory B-ALL},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
volume = {14},
number = {9},
pages = {e015196},
doi = {10.1136/jitc-2026-015196}
}
EUVIMED